Singapore markets closed
Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,117.30 +38.44 (+0.48%) Bitcoin USD
64,180.15 +457.99 (+0.72%) CMC Crypto 200
1,383.80 -12.74 (-0.91%)
ARS Pharmaceuticals, Inc. (SPRY)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 8.26 |
| Open | 8.01 |
| Bid | 8.08 x 100 |
| Ask | 8.12 x 400 |
| Day's range | 7.67 - 8.18 |
| 52-week range | 2.55 - 11.27 |
| Volume | |
| Avg. volume | 697,387 |
| Market cap | 780.698M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Barrons.com
ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
RA Capital increased its stake in biopharmaceutical firm ARS. Bain Capital lowered its stake in pharmaceutical firm Nuvalent.
- Simply Wall St.
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Zacks
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should Know
ARS Pharmaceuticals, Inc. (SPRY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
© 2024 Yahoo. All rights reserved.